Recent data show that more than 60% of new drugs approved in recent years come from small to mid-sized biotech and biopharma companies, not from the top 30 large pharmaceutical firms. This trend points out the important role these companies have in creating new medicines. Smaller biotechs have fewer rules, faster decision-making, and take more risks. This helps them develop new treatments faster than big companies.
In this setting, smaller Clinical Research Organizations (CROs) have become key partners. These groups provide clinical research help that meets the specific needs of smaller companies. Smaller companies often do not have many resources or big clinical departments. Large CROs may have trouble giving personal attention to small clients. Mid-sized CROs like Worldwide Clinical Trials and Allucent offer better access to clinical teams and senior managers. This helps biotech companies respond quickly to problems during trials and regulatory steps.
Smaller CROs often focus on hard and special therapeutic areas such as cancer, immune diseases, brain disorders, rare diseases, and cell and gene therapies. Their special knowledge makes sure biotech firms get help suited to their patient groups and drug types.
North Carolina is a strong area for clinical research outsourcing. The state has about 167 CROs employing over 24,600 people. This shows how important clinical research services are to the US economy. Big companies like Iqvia and PPD are based there. They help build a close network of clinical research skill, biomedical innovation, and outsourcing services.
In 2024, North Carolina saw clinical trial starts go up by 32% and biopharma funding increase by 56% from the year before. This shows good chances for more growth in clinical research outsourcing. Both US and foreign drug companies rely more on CRO services for their trials. New biotech companies often prefer smaller and medium CROs that offer more flexibility and special help.
Velocity Clinical Research, based in North Carolina, shows growth and change in this field. From 2021 to 2024, Velocity grew from 14 to 90 clinical sites worldwide. It ran trials for all companies involved in Operation Warp Speed during the COVID-19 crisis. The company notes that the field has moved from just efficiency improvements to using artificial intelligence (AI) to improve trial quality and speed up drug development.
In North Carolina, the biggest CROs control about 70% of the market. But this leaves room for smaller firms to meet special needs with personal service, especially for biotechs that feel ignored by bigger companies.
Even with these challenges, smaller CROs keep making changes in how they work. They find ways to give expert service and flexible support to biotech clients.
Artificial intelligence (AI) and automation have become key tools in clinical research, including in smaller CROs. Using AI in office and admin tasks makes work faster, cuts errors, and speeds up trials.
Companies like Velocity Clinical Research say AI first helped clinical research by making back-office work more efficient. Now AI is used in bigger ways, like finding right patients from large data and improving trial plans.
Smaller CROs use AI tools to:
With AI-powered answering services and phone automation, CROs improve communication between study teams, sponsors, and patients. This lowers admin work and makes responses faster.
In healthcare admin, where time and accuracy matter, AI tools help make clinical trial management better. Smaller CROs rely on these tools to compete with bigger firms.
Big pharmaceutical companies often focus on adding to their existing drug lines. They usually avoid high risks and have complex structures. Smaller and mid-sized biotech companies work on new types of therapies for new disease areas. CROs supporting these biotechs must have science knowledge, strong operations, and close client attention.
Worldwide Clinical Trials says they commit to small biotech clients by giving full access to clinical teams and senior leaders. This ensures client needs are met with flexibility and quick responses. One clinical research expert said, “We’re big enough to matter, and small enough to care.”
Allucent focuses on mixing different expert knowledge and personal communication. This helps smaller biotech clients move from early discovery to late-stage trials and regulatory steps with fewer delays and less paperwork.
Healthcare IT managers, administrators, and medical practice owners involved in clinical research should know the benefits and limits of working with smaller CROs. These partnerships allow more flexible clinical development that fits complex treatments needing close attention and custom support.
Medical administrators, practice owners, and IT managers thinking about clinical trials can find smaller CROs useful to support innovation while controlling costs and managing operations.
Through these partnerships and new technologies, smaller clinical research organizations continue to help biotech innovation move forward across the United States.
AI is poised to transform North Carolina’s clinical research outsourcing industry by enhancing efficiency, reducing administrative costs, accelerating patient enrollment for trials, and improving data utilization.
The pandemic spurred growth in trial activity, supported by increased R&D spending, especially from emerging biopharma companies. This has led to a positive shift in the market dynamics.
Major players include Iqvia and PPD, which have significantly contributed to the state’s CRO ecosystem, benefiting from local research universities and pharmaceutical companies.
Smaller CROs differentiate themselves by offering specialized services and greater customer attention, positioning themselves as valuable partners to biotech companies that may feel overlooked by larger firms.
There’s a significant appetite from private equity for CROs, leading to a consolidation trend where larger firms acquire smaller ones to expand their expertise and service offerings.
One major challenge is ensuring high-quality data for AI training, as the quality of electronic medical records can vary, affecting AI’s efficacy in patient recruitment and data analysis.
CROs are increasingly specializing in specific therapies to cater to emerging biopharma companies, which are more likely to outsource rather than build in-house capabilities.
Consolidation allows larger CROs to dominate the market share but also opens up opportunities for smaller firms to capture unmet needs in service provision and innovation.
Biopharma funding saw a 56% increase early this year, while clinical trial starts rose 32%, indicating a recovery and positive outlook for the future of drug development.
Velocity emerged as a leader by conducting trials for all pharma companies involved in Operation Warp Speed, rapidly growing its operational footprint and database of patients during the crisis.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
